The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be ...

Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...